28 results
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Recommendations for Preventing ... Preventing First ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Recommendations for Preventing ... ) in HIV-AIDS Preventing ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
Pain, Agitation, and Delirium (PAD) in the ICU
Addressing the ICU Triad (PAD) can be accomplished through
Pain, Agitation, ... No pharmacologic ... be effective in preventing ... be effective in preventing ... CriticalCare #diagnosis #management
Gamma hydroxybutyrate (GHB) - Toxicology

Clinical presentation
 - Symptoms of GHB toxicity include: short term anterograde amnesia,
toxicity include: short ... symptoms can include agitation ... Toxicity #Diagnosis #Management ... #Pharmacology
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Recommendations for Preventing ... #Treatment #opportunistic ... infections #HIVAIDS #management ... #pharmacology # ... pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
mucosal #IDSA #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
Medical Treatment Algorithm for Chronic Obstructive Pulmonary Disease
Initial medical treatment of chronic obstructive pulmonary disease (COPD)
COPD assessment test ... antagonist; SABA, short-acting ... agonist; SAMA, short-acting ... Treatment #Algorithm #Management ... SABA #SAMA #ICS #Pharmacology